Acquisition provides Pfizer with a preclinical CMV vaccine candidate Pfizer Inc.

Microbiol. Rev. 2013 vol January. 26 no. 1 86-102 4. Cannon, MJ. Et. Al., Washing our Hands of the Congenital Cytomegalovirus Disease Epidemic, BMC Public Wellness., 2005; 5:70 5. CDC website: ; accessed October 28, 2014 6. Arvin, A. Et. Al. Adeno-associated virus type 2 is certainly a virus that regularly infects human beings but causes no disease. Past studies by the same experts show that it promotes tumor cell death in cervical malignancy cells infected with human papillomavirus. Experts used an unaltered, normally occurring version of AAV2 on human breast cancer cells. Breast cancer may be the most prevalent cancers in the globe and may be the leading cause of cancer-related death in females, said Samina Alam, Ph.D., research associate in microbiology and immunology.The body fuel shouldn’t lightly be taken.. AbbVie selects Halozyme’s ENHANZE platform to augment their advancement pipeline Halozyme Therapeutics, Inc. Beneath the terms of the agreement, Halozyme will receive an initial $23 million payment, followed by milestone payments totaling approximately $130 million for every as high as nine collaboration targets. These payments are subject to AbbVie's achievement of specified development, regulatory and sales-based milestones. In addition, AbbVie can pay Halozyme tiered royalties if products under the collaboration are commercialized. Related StoriesMD Anderson research reveals why chemotherapy medications not effective for many pancreatic cancer patientsStudy shows rare HER2 missense mutations do not spread breast cancer on the ownNew results reveal association between colorectal cancer tumor and melanoma drug treatmentThe Halozyme ENHANZE platform is founded on a proprietary recombinant human being hyaluronidase enzyme that temporarily degrades hyaluronan, a chain of natural sugars in the physical body, to assist in the absorption and dispersion of additional injected therapeutic drugs.